Organization · Venture Capital
AVANT BIO
AVANT BIO is a New York-based investment firm specializing in early-stage and growth equity investments in life sciences, tech bio, and healthtech sectors. The firm focuses on therapeutic enabling technologies and innovative solutions that merge biology with advanced technologies.
Overview
What AVANT BIO does
What AVANT BIO is
AVANT BIO is a New York-based investment firm specializing in early-stage and growth equity investments in life sciences, tech bio, and healthtech sectors. The firm focuses on therapeutic enabling technologies and innovative solutions that merge biology with advanced technologies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find AVANT BIO elsewhere
Open the official website or a supported primary organization account.
Capability profile
AVANT BIO as a funder
Investment thesis
AVANT BIO invests in the enabling layer behind future therapeutics, focusing on tools, technologies, and services that facilitate therapeutic discovery, development, and manufacturing.
Focus narrative
AVANT BIO invests in therapeutic enabling technologies, biomanufacturing tools and automation, machine learning and AI applications, healthtech, techbio, and contract services. Their thematic focus includes innovations that enhance drug discovery and manufacturing processes, ensuring that therapies are accessible and effective.
Value beyond capital
AVANT BIO provides active support to its portfolio companies by leveraging domain expertise in life sciences and technology. The firm focuses on enhancing operational efficiencies and facilitating access to critical resources, thereby accelerating the development and commercialization of innovative therapeutics.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Growth Equity
- Regions
- North America · Europe · Global
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
AVANT BIO's portfolio includes notable companies such as: Better Medicine, Faster with AI and Lab Automation: Active investment since 2025, based in Toronto, Ontario, Canada. Protein Profiling, Unleashed: Active investment since 2025, based in Montréal, Québec, Canada. Image Management Simplified: Active investment since 2025, based in Montville, NJ, USA. Innovating Cell Culture: Active investment since 2025, based in Aachen, Germany. Innovating Cell Culture: Active investment since 2026, based in Paris, France.
Common questions
What to know about AVANT BIO
Upseed classifies AVANT BIO under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.